Vertex Pharmaceuticals Inc

18 sept. 2026, 20:07 UTC

Vertex Pharmaceuticals Inc shares fell sharply, continuing a decline since Thursday's close, amid broader market losses and remaining below its 20-day moving average.

17 sept. 2026, 20:07 UTC

Vertex Pharmaceuticals Inc. is trading modestly higher, despite fluctuations and positioning near the lower end of its one-month range.

16 sept. 2026, 23:01 UTC

Vertex Pharmaceuticals Inc is trading modestly lower in after-market hours, reaching its lowest point just before 6:00 PM and remaining below its 20-day moving average.

15 sept. 2026, 20:07 UTC

Vertex Pharmaceuticals is trading lower, reaching a four-week low of $511.15, despite a partnership with Lindsey Vonn to promote JOURNAVX.

14 sept. 2026, 22:01 UTC

Vertex Pharmaceuticals Inc shares are lower in after-market hours, following a brief rise after Monday's close. No specific news was identified to explain the decline.

11 sept. 2026, 23:06 UTC

Vertex Pharmaceuticals Inc. shares are lower in after-market hours, reflecting a slight decline since Friday's close amid broader market conditions and rising inflation data.

10 sept. 2026, 19:16 UTC

Vertex Pharmaceuticals is declining for a fourth consecutive session amid scrutiny over drug pricing and competition, despite an earlier rebound from session highs.

9 sept. 2026, 23:41 UTC

Vertex Pharmaceuticals shares are trading higher in after-market hours, recovering from declines in the previous three sessions. No specific news was identified for this movement.

8 sept. 2026, 20:02 UTC

Vertex Pharmaceuticals is trading lower amid a notable decline in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

4 sept. 2026, 23:30 UTC

Vertex Pharmaceuticals shares are higher in after-market trading, despite declining from an initial peak. No specific news was identified to explain the movement.

2 sept. 2026, 19:56 UTC

Morgan Stanley reinstated its Overweight rating on Vertex Pharmaceuticals, setting a price target of $665 following the acquisition of Crinetics Pharmaceuticals.

1 sept. 2026, 20:08 UTC

Vertex Pharmaceuticals is rising following its $10 billion acquisition of Crinetics Pharmaceuticals, which aims to enhance its innovation pipeline and revenue growth.

31 aug. 2026, 20:07 UTC

Vertex Pharmaceuticals shares are higher, reflecting broader market gains amid inflation concerns and potential monetary tightening discussed at the Jackson Hole Symposium.

27 aug. 2026, 20:07 UTC

Vertex Pharmaceuticals shares are roughly flat as market performance remains stable. Initial jobless claims declined, indicating resilience in the labor market.

26 aug. 2026, 23:06 UTC

Vertex Pharmaceuticals shares are trading lower in after-market hours. No specific news was identified to explain the price movement.

24 aug. 2026, 19:16 UTC

Vertex Pharmaceuticals shares are little changed amid minor fluctuations. Market participants await upcoming events, including a speech by Federal Reserve Chair Kevin Warsh.

21 aug. 2026, 19:26 UTC

Vertex Pharmaceuticals is trading higher, reflecting a broader rebound in U.S. stocks amid increased market sentiment and notable volatility during the session.

20 aug. 2026, 20:02 UTC

Vertex Pharmaceuticals shares are lower today, reflecting broader market pressures after Walmart's disappointing sales report raised concerns about consumer spending.

19 aug. 2026, 23:46 UTC

Vertex Pharmaceuticals shares are trading roughly flat in after-market hours. The stock remains above its 20-day moving average and has finished higher for four consecutive sessions.

18 aug. 2026, 20:03 UTC

Vertex Pharmaceuticals shares are higher today, continuing a notable upward trend since Monday. No specific company news was identified to explain the advance.

17 aug. 2026, 23:36 UTC

Vertex Pharmaceuticals shares are trading higher in after-market hours. No specific news was identified to explain this movement amid a lower broader market.

14 aug. 2026, 20:02 UTC

Vertex Pharmaceuticals is lower today, marking four straight days of declines. Broader market sentiment may be affected by a drop in U.S. retail sales.

13 aug. 2026, 23:26 UTC

Vertex Pharmaceuticals shares are higher in after-market hours, following a modest decline earlier. The stock remains above its 20-day moving average.

12 aug. 2026, 19:42 UTC

Vertex Pharmaceuticals is trading lower today, pulling back from an earlier session high. No specific news has been identified to explain the decline.

11 aug. 2026, 19:36 UTC

Vertex Pharmaceuticals gained today after Bank of America Merrill Lynch added it to the US 1 List, reflecting strong confidence in its future prospects.

10 aug. 2026, 20:02 UTC

Vertex Pharmaceuticals shares rose following Sionna Therapeutics' trial failure, easing competitive pressure on Trikafta. BMO analyst noted this as a positive for Vertex's franchise.

7 aug. 2026, 19:51 UTC

Vertex Pharmaceuticals shares are higher as the Biotechnology sector strengthens. The company reported $3.33 billion in second-quarter revenue, driven by cystic fibrosis sales.

6 aug. 2026, 19:26 UTC

Vertex Pharmaceuticals is trading near unchanged levels with no specific news identified. The stock remains within a narrow range today.

5 aug. 2026, 19:16 UTC

Vertex Pharmaceuticals shares are higher as Barclays raises its price target to $617. Truist maintains a Buy rating and sets a target of $565.

4 aug. 2026, 20:05 UTC

Vertex Pharmaceuticals is rising today, buoyed by analyst upgrades and a strong Q2 revenue of $3.33 billion, with TD Cowen raising its target to $550.